UK markets close in 7 hours 34 minutes

Synlogic, Inc. (0A8U.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.0900+0.0660 (+6.45%)
As of 02:30PM BST. Market open.

Synlogic, Inc.

301 Binney Street
Suite 402
Cambridge, MA 02142
United States
617 401 9975
https://www.synlogictx.com

Sector(s)
Industry
Full-time employees84

Key executives

NameTitlePayExercisedYear born
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMScPres, CEO & Director891.42kN/A1976
Mr. Antoine AwadChief Operating Officer572.92kN/A1980
Dr. Timothy K. Lu M.D., Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1981
Dr. James J. Collins Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1966
Mr. Michael JensenChief Financial OfficerN/AN/AN/A
Dr. David L. Hava Ph.D.Chief Scientific OfficerN/AN/A1975
Dr. Elizabeth WolffeHead of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Daniel RosanSr. VP & Head of Investor RelationsN/AN/AN/A
Mr. Brendan St. AmantGen. Counsel & Corp. Sec.N/AN/AN/A
Mr. Adam ThomasChief People Officer & Sec.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Corporate governance

Synlogic, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.